Derivation Web

source_f826b6435cb4475c

by researka:v2 · 2026-07-15 12:35:43.972602+04:00

# Research Synthesis: Protein supplementation — full paper

## Abstract

This paper synthesizes evidence on Protein supplementation across 41 accepted source papers and 2443 high-confidence extracted claims.

The evidence profile contains 11 direct clinical sources, 30 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

Positive study-level signals are summarized in the muscle function and contextual adjacent evidence outcome classes, null signals in the muscle function, frailty and cardiometabolic outcome classes, and negative signals in the muscle function and frailty outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Protein supplementation remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

In this section, the paragraph is tied to the local interpretive task. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

## Introduction

This synthesis evaluates evidence on Protein supplementation across 41 included source papers and 2443 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 11 direct clinical sources, 30 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for Protein supplementation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Huschtscha 2021, Kittiskulnam 2022, Kirk 2021 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the muscle function and contextual adjacent evidence outcome classes; null signals around the muscle function, frailty and cardiometabolic outcome classes; and negative or adverse signals around the muscle function and frailty outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Inferential Bridge

[inferential bridge status: not established]

No inferential bridge claim is made. Mechanistic plausibility can coexist with sparse direct human evidence, but the mechanistic-to-clinical and biomarker-to-bedside bridges remain untested by the retained corpus. Population-to-population transfer is therefore unsupported, and cross-domain interpretation is bounded to hypothesis generation rather than clinical efficacy.

## Methods

Risk-of-bias appraisal summary: The public appraisal artifact reports 41 source-level rating row(s) using ROBINS-I, RoB-2, SYRCLE; overall ratings are some concerns=41. These ratings summarize preliminary source-level appraisal and do not upgrade indirect or adjacent evidence into direct clinical proof.

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-protein_nutrition-v06-DAILY-2026-07-15T08-19-35Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-15.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `protein supplementation AND older adults AND randomized trial`
- `whey protein AND sarcopenia AND elderly`
- `leucine AND muscle mass AND aging`
- `dietary protein AND frailty AND older adults`
- `essential amino acids AND older adults AND physical function`

### Eligibility criteria
- Sources whose primary content addresses protein nutrition.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 169 records in the receipt-candidate union, 49 were classified as source candidates and 41 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 169 |
| Classified source candidates | 49 |
| No extractable claims | 26 |
| None-only claim binding | 8 |
| Mixed partial-or-none claim-binding candidates | 39 |
| Partial-only claim-binding candidates | 25 |
| Strict high-confidence sources | 22 |
| Admitted final sources | 41 |

Admission-bucket note: The funnel rows are audit categories, not an additive conservation table. No-extractable-claim, mixed partial-or-none, partial-only, and admitted-final-source counts can be equal or overlap because they describe different screening and claim-binding states; final source admission is the retained-source count after deduplication and eligibility, not the complement of any one exclusion row. Diagnostic bucket glossary: classified source candidates are the parent evaluated set; strict high-confidence, partial-only, mixed partial-or-none, none-only, and no extractable claims are overlapping audit states; admitted final sources are the frozen manuscript denominator. Auditable arithmetic is therefore candidate union -> classified source candidates -> admitted final sources, while diagnostic bucket rows do not sum to the classified count. Source-selection interpretation: 41 admitted sources came from 49 classified source candidates after deduplication, active-scope filtering, claim-binding confidence, and eligibility checks. The other source-selection buckets are overlapping diagnostic states, not a simple excluded = candidates - admitted count. Stepwise reconciliation: classified source candidates (49) -> admitted final sources (41); not admitted after deduplication, active-scope filtering, claim-binding confidence, and eligibility checks = 8. Strict high-confidence subset note: 22 strict high-confidence receipt(s) are a quality subset, not the synthesis denominator; the admitted source base remains 41.

### Exclusion reasons
- Exclusion accounting is captured in the source-admission funnel above: retrieval, deduplication, claim-binding, and strict high-confidence admission reduce source candidates to the retained source set. The audit buckets are overlapping and non-additive, so the manuscript does not infer a simple excluded = candidates - admitted count.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, frailty, immune and inflammation, longevity, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Topic-fit rationale: Sources are retained only when they operationalize protein nutrition directly or provide adjacent/contextual boundary evidence for the same construct. 11/41 retained sources are classified as direct; adjacent, contextual, review-level, or mechanistic sources are reclassified as boundary evidence rather than used for broad efficacy claims. Representative source-fit checks: Huschtscha 2021 (direct; Muscle Function), Griffen 2022 (indirect; Contextual Adjacent Evidence), Jackson 2022 (indirect; Muscle Function), Kittiskulnam 2022 (direct; Contextual Adjacent Evidence), Kirk 2021 (direct; Contextual Adjacent Evidence).

### Findings Map

Findings Map completeness note: all 41 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Hashimoto 2020: Effect of Exercise Habit on Skeletal Muscle Mass Varies with Protein Intake in Elderly Patients with Type 2 Diabetes: A Retrospective Cohort Study | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.078; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Honaga 2022: Investigation of the Effect of Nutritional Supplementation with Whey Protein and Vitamin D on Muscle Mass and Muscle Quality in Subacute Post-Stroke Rehabilitation Patients: A Randomized, Single-Blinded, Placebo-Controlled Trial | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=representative non-significant statistic P = 0.217; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Kalyva 2026: Effects of Higher Dietary Protein Intake on Isokinetic Muscle Performance in Older Adults with Type 2 Diabetes Mellitus | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Griffen 2022: Changes in 24‐h energy expenditure, substrate oxidation, and body composition following resistance exercise and a high protein diet via whey protein supplementation in healthy older men | direction=mixed | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Helder 2020: Blended home‐based exercise and dietary protein in community‐dwelling older adults: a cluster randomized controlled trial | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Jacob 2021: Mitochondrial Content, but Not Function, Is Altered With a Multimodal Resistance Training Protocol and Adequate Protein Intake in Leucine-Supplemented Pre/Frail Women | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.012; source-level statistic reported |
| Contextual Adjacent Evidence | Kirk 2021: Leucine‐enriched whey protein supplementation, resistance‐based exercise, and cardiometabolic health in older adults: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Kittiskulnam 2022: The beneficial effects of intradialytic parenteral nutrition in hemodialysis patients with protein energy wasting: a prospective randomized controlled trial | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Kwok 2023: Exploring the short‐term impact of swapping consumption from standard protein snacks to higher protein snacks on energy intake in social drinkers: Is protein worth a nudge? | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Yang 2024: FEASIBILITY OF WHEY PROTEIN SUPPLEMENTATION TO IMPROVE OLDER ADULT FUNCTION POST-HOSPITALIZATION | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=3 extracted claim(s); source-level direction is the coded finding |
| Deficiency Prevalence | Aguilera 2025: Dileucine-supplemented essential amino acids support whole-body anabolism after resistance exercise and serum-stimulated cell-based anabolism | direction=unclear | directness=indirect | B2 | outcome=Mechanism/Deficiency Prevalence (cell/in vitro); direction=unclear | finding=representative non-significant statistic P = 0.68; not treated as positive or negative directional support unless source direction is coded |
| Frailty | Amasene 2021: Effects of Resistance Training Intervention along with Leucine-Enriched Whey Protein Supplementation on Sarcopenia and Frailty in Post-Hospitalized Older Adults: Preliminary Findings of a Randomized Controlled Trial | direction=negative | directness=direct | A1 | outcome=Frailty; direction=negative | finding=representative statistic P < 0.005; source-level statistic reported |
| Frailty | Cereda 2022: Whey Protein, Leucine- and Vitamin-D-Enriched Oral Nutritional Supplementation for the Treatment of Sarcopenia | direction=null | directness=indirect | B2 | outcome=Frailty; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding |
| Frailty | Cheah 2023: Benefits and side effects of protein supplementation and exercise in sarcopenic obesity: A scoping review | direction=unclear | directness=review | B1 | outcome=Frailty; direction=unclear | finding=11 extracted claim(s); source-level direction is the coded finding |
| Frailty | Han 2024: Association of Protein Intake with Sarcopenia and Related Indicators Among Korean Older Adults: A Systematic Review and Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Frailty; direction=unclear | finding=96 extracted claim(s); source-level direction is the coded finding |
| Frailty | Kaminska 2023: The Impact of Whey Protein Supplementation on Sarcopenia Progression among the Elderly: A Systematic Review and Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Frailty; direction=unclear | finding=representative non-significant statistic P = 0.171; not treated as positive or negative directional support unless source direction is coded |
| Frailty | Li 2024: Effect of Protein Supplementation Combined With Resistance Training in Gait Speed in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | direction=unclear | directness=review | B1 | outcome=Frailty; direction=unclear | finding=3 extracted claim(s); source-level direction is the coded finding |
| Frailty | Travers 2021: Protocol for a randomised controlled trial of a primary care intervention to Reverse Frailty and Enhance Resilience through Exercise and dietary protein Education (REFEREE) in community-dwelling adults aged 65 and over | direction=null | directness=direct | A1 | outcome=Frailty; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding |
| Frailty | Wu 2025: Dietary protein requirements of older adults with sarcopenia determined by the indicator amino acid oxidation technology | direction=mixed | directness=indirect | B2 | outcome=Frailty; direction=mixed | finding=representative non-significant statistic P = 0.6148; not treated as positive or negative directional support unless source direction is coded |
| Immune and Inflammation | Merchant 2023: Impact of exercise and leucine-enriched protein supplementation on physical function, body composition, and inflammation in pre-frail older adults: a quasi-experimental study | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=representative statistic P = 0.005; source-level statistic reported |
| Longevity | Sun 2021: Association of Major Dietary Protein Sources With All‐Cause and Cause‐Specific Mortality: Prospective Cohort Study | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=41 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Bulow 2023: Effect of 1-year daily protein supplementation and physical exercise on muscle protein synthesis rate and muscle metabolome in healthy older Danes: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative non-significant statistic P = 0.75; not treated as positive or negative directional support unless source direction is coded |
| Muscle Function | Chang 2023: Effects of Whey Protein, Leucine, and Vitamin D Supplementation in Patients with Sarcopenia: A Systematic Review and Meta-Analysis | direction=mixed | directness=review | B1 | outcome=Muscle Function; direction=mixed | finding=representative statistic P = 0.003; source-level statistic reported |
| Muscle Function | Cuyul-Vasquez 2023: Effectiveness of Whey Protein Supplementation during Resistance Exercise Training on Skeletal Muscle Mass and Strength in Older People with Sarcopenia: A Systematic Review and Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.01; source-level statistic reported |
| Muscle Function | Hoekstra 2024: The effect of home‐based neuromuscular electrical stimulation‐resistance training and protein supplementation on lean mass in persons with spinal cord injury: A pilot study | direction=mixed | directness=indirect | B2 | outcome=Muscle Function; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Huschtscha 2021: The Effects of a High-Protein Dairy Milk Beverage With or Without Progressive Resistance Training on Fat-Free Mass, Skeletal Muscle Strength and Power, and Functional Performance in Healthy Active Older Adults: A 12-Week Randomized Controlled Trial | direction=negative | directness=direct | A1 | outcome=Muscle Function; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Ijaz 2025: Enhancing Muscle Quality: Exploring Leucine and Whey Protein in Sarcopenic Individuals | direction=positive | directness=indirect | B2 | outcome=Muscle Function; direction=positive | finding=representative statistic P < 0.01; source-level statistic reported |
| Muscle Function | Jackson 2022: Effectiveness of a Per-Meal Protein Prescription and Nutrition Education with versus without Diet Coaching on Dietary Protein Intake and Muscle Health in Middle-Aged Women | direction=negative | directness=indirect | B2 | outcome=Muscle Function; direction=negative | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Justesen 2022: Comparing Even with Skewed Dietary Protein Distribution Shows No Difference in Muscle Protein Synthesis or Amino Acid Utilization in Healthy Older Individuals: A Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Muscle Function; direction=null | finding=representative non-significant statistic P = 0.647; not treated as positive or negative directional support unless source direction is coded |
| Muscle Function | Khalafi 2025: Effects of Whey Protein Supplementation on Body Composition, Muscular Strength, and Cardiometabolic Health in Older Adults: A Systematic Review with Pairwise Meta-Analysis | direction=unclear | directness=review | B2 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.007; source-level statistic reported |
| Muscle Function | Kwon 2023: Improved Muscle Mass and Function With Protein Supplementation in Older Adults With Sarcopenia: A Meta-Analysis | direction=positive | directness=review | B2 | outcome=Muscle Function; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Nasimi 2023: Whey Protein Supplementation with or without Vitamin D on Sarcopenia-Related Measures: A Systematic Review and Meta-Analysis | direction=unclear | directness=review | B1 | outcome=Muscle Function; direction=unclear | finding=38 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Noh 2023: Effects of resistance training and protein supplementation interventions on muscle volume and muscle function: sex differences in humans | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=32 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Nunes 2022: Systematic review and meta‐analysis of protein intake to support muscle mass and function in healthy adults | direction=mixed | directness=review | B1 | outcome=Muscle Function; direction=mixed | finding=representative statistic P < 0.01; source-level statistic reported |
| Muscle Function | Pearson 2022: The impact of dietary protein supplementation on recovery from resistance exercise-induced muscle damage: A systematic review with meta-analysis | direction=negative | directness=review | B1 | outcome=Muscle Function; direction=negative | finding=75 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Peng 2024: Protein‐enriched soup and weekly exercise improve muscle health: A randomized trial in mid‐to‐old age with inadequate protein intake | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.006; source-level statistic reported |
| Muscle Function | Salas-Groves 2024: The Effect of Web-Based Culinary Medicine to Enhance Protein Intake on Muscle Quality in Older Adults: Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Muscle Function; direction=null | finding=representative non-significant statistic P = 0.88; not treated as positive or negative directional support unless source direction is coded |
| Muscle Function | Santos 2023: Effects of Whey Protein Isolate on Body Composition, Muscle Mass, and Strength of Chronic Heart Failure Patients: A Randomized Clinical Trial | direction=unclear | directness=direct | A1 | outcome=Muscle Function; direction=unclear | finding=representative statistic P = 0.007; source-level statistic reported |
| Muscle Function | So 2020: Effect of Dairy Protein Intake on Muscle Mass among Korean Adults: A Prospective Cohort Study | direction=positive | directness=indirect | B2 | outcome=Muscle Function; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Stahn 2020: Combined protein and calcium β-hydroxy-β-methylbutyrate induced gains in leg fat free mass: a double-blinded, placebo-controlled study | direction=positive | directness=indirect | B2 | outcome=Muscle Function; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Muscle Function | Zaromskyte 2021: Evaluating the Leucine Trigger Hypothesis to Explain the Post-prandial Regulation of Muscle Protein Synthesis in Young and Older Adults: A Systematic Review | direction=null | directness=review | B2 | outcome=Muscle Function; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Protein supplementation / Muscle Function | n=20; claims=1304 | significant source statistic in 15/20 sources; receipt-level direction coded unclear | 6 direct; 6 indirect; 8 review | limited corpus depth in this outcome class |
| Protein supplementation / Frailty | n=8; claims=232 | significant source statistic in 3/8 sources; receipt-level direction coded unclear | 2 direct; 2 indirect; 4 review | limited corpus depth in this outcome class |
| Protein supplementation / Contextual Adjacent Evidence | n=7; claims=608 | significant source statistic in 6/7 sources; receipt-level direction coded unclear | 3 direct; 4 indirect | limited corpus depth in this outcome class |
| Protein supplementation / Cardiometabolic | n=3; claims=100 | significant source statistic in 3/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class |
| Protein supplementation / Deficiency Prevalence | n=1; claims=74 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Protein supplementation / Immune and Inflammation | n=1; claims=84 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| Protein supplementation / Longevity | n=1; claims=41 | unclear signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Skeletal and muscle context: 22 sources; significant source statistic in 17/22 sources; receipt-level direction coded unclear.
- Aging and geroscience context: 8 sources; significant source statistic in 6/8 sources; receipt-level direction coded unclear.

### Results Summary

- Muscle Function: n=20; claims=1304; mixed signal in 8/20 sources | directness: 6 direct; 6 indirect; 8 review; main limitation: directionally heterogeneous.
- Frailty: n=8; claims=232; mixed signal in 4/8 sources | directness: 2 direct; 2 indirect; 4 review; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=7; claims=608; benefit signal in 3/7 sources | directness: 3 direct; 4 indirect; main limitation: directionally heterogeneous.
- Cardiometabolic: n=3; claims=100; mixed signal in 2/3 sources | directness: 2 indirect; 1 review; main limitation: no direct clinical anchor.
- Deficiency Prevalence: n=1; claims=74; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=1; claims=84; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Three observational cohorts in the Protein corpus examine cardiometabolic outcomes in populations defined by glucose-handling status or recent vascular injury. Hashimoto 2020 retrospectively stratified type 2 diabetes patients by exercise habit and protein intake adequacy, while Honaga 2022 conducted a randomized, single-blinded, placebo-controlled trial of whey protein plus vitamin D in subacute post-stroke rehabilitation patients. The three studies span dietary protein supplementation, behavioral stratification, and post-stroke nutritional recovery as distinct exposure modalities within a single shared cardiometabolic outcome class.

Quantitative findings across the three cardiometabolic studies are heterogeneous rather than converging. Honaga 2022 reports P = 0.217 for its primary contrast alongside P < 0.05 for selected secondary outcomes. The full per-study p-value and odds-ratio inventory is tabulated in the evidence synthesis (Per-Study Endpoint Evidence).

Mechanistically, the three sources converge on a substrate-level rationale: older adults with T2DM, post-stroke inpatients, and sarcopenia-defined cohorts all share reduced anabolic responsiveness and elevated catabolic signaling, conditions under which amino-acid availability would be expected to modulate lean mass and strength endpoints. Preclinical data (referenced indirectly through the protein-intake literature) and observational human evidence both support protein as a permissive substrate for muscle protein synthesis, but the within-corpus RCT-level demonstration of clinically meaningful cardiometabolic-muscle benefit is sparse. By contrast, the three sources in this outcome class are all rated as indirect or review in directness, and none is anchored to a canonical trial identifier, which limits causal attribution. The mechanistic substrate underlying these functional signals is biologically coherent, but the human-RCT bridge from mechanistic plausibility to bedside endpoint remains underdeveloped in the current corpus.

### Contextual Adjacent Evidence Outcomes

Trial summary. The contextual outcome class aggregates evidence from seven sources spanning clinical RCTs and observational cohorts in adults and older adults. Helder 2020 was a cluster randomized controlled trial of blended home-based exercise plus a dietary protein intervention in community-dwelling older adults, with 6- and 12-month effectiveness endpoints (Helder 2020). Kittiskulnam 2022 was a prospective RCT of intradialytic parenteral nutrition (IDPN) in maintenance hemodialysis patients with protein-energy wasting, comparing IDPN against standard oral nutritional support in those unable to tolerate ONS (Kittiskulnam 2022). Kirk 2021 was the 16-week Liverpool Hope University-Sarcopenia Aging Trial (LHU-SAT).

Quantitative findings. Detailed per-study endpoint p-values are catalogued in the evidence synthesis; this paragraph summarizes source-traced signals without restating each tuple. Kittiskulnam 2022 reported P = 0.01, P = 0.04, P = 0.03, P = 0.006, P = 0.001, P = 0.004, P < 0.01, P < 0.01, P < 0.05, P = 0.005, and P = 0.02 in its IDPN versus standard-care biomarker and nutritional-status battery (Kittiskulnam 2022). Kirk 2021 reported P < 0.001, P = 0.002, P = 0.003, P = 0.001, P = 0.009, P = 0.007, P = 0.048, and P > 0.05 across its cardiometabolic and functional endpoints (Kirk 2021). Yang 2024 contributed feasibility adherence numerics rather than inferential p-values (Yang 2024).

Mechanism. The mechanistic substrate underlying the contextual outcomes reported across this class is plausibly convergent but not uniformly demonstrated. Mechanistically, leucine-enriched whey supplementation in Kirk 2021 was paired with resistance-based exercise and produced changes in cardiometabolic readouts, consistent with the amino-acid-driven mTORC1 activation model that underpins most rationale for higher protein intake in older adults (Kirk 2021).

Within-corpus tensions. The contextual outcome class carries both inferential and design-related disagreements that warrant explicit discussion. Helder 2020 and Kittiskulnam 2022, by contrast, agree in reporting positive directional effects on this outcome class, with Helder 2020 at P = 0.001 and Kittiskulnam 2022 at P = 0.001 for headline endpoints (Helder 2020; Kittiskulnam 2022). The trial's directness to a community-dwelling older-adult deficiency prevalence question is indirect, given the young, healthy cohort and the exercise-challenge paradigm rather than a free-living dietary intake survey. Numerator-level endpoints are densely reported in the source, with multiple p-values spanning P = 0.68, P < 0.0001, P = 0.31, P = 0.59, P = 0.39, P = 0.50, P = 0.55, P = 0.086, P = 0.003, P < 0.001, P = 0.011, P = 0.002, P = 0.047, P < 0.05, P < 0.0001, P = 0.678, and P = 0.583. Effect direction is flagged as unclear, reflecting that several of these p-values correspond to null contrasts against comparator.

Mechanistically, the anabolic biomarker signal is anchored in serum-stimulated cell-based anabolism assays combined with whole-body turnover read-outs after resistance exercise, positioning the trial as a translational bridge between in vitro leucine sensing and in vivo muscle protein synthesis. By contrast, the population is young and healthy (24 ± 3 y), so the mechanistic substrate underlying this functional finding — mTORC1 activation, leucine-mediated translation initiation — does not transfer cleanly to a free-living older-adult deficiency prevalence question. Within the corpus, deficiency prevalence is therefore represented by a single mechanistic human study whose endpoint set mixes stable-isotope/serum biomarker outcomes with classical anabolism assays, and the direction of the population-to-population transfer gap is explicitly flagged by the indirect directness coding.

Because the cross-study disagreement map lists no same-outcome non-orthogonal pairs for deficiency prevalence, within-corpus tensions cannot be named by source pair in this subsection. Across the corpus, the deficiency prevalence class therefore carries sparse, indirect, and mechanistically suggestive rather than epidemiologically conclusive evidence, consistent with the picked thesis statement that mechanistic plausibility coexists with mixed or sparse human data.

### Frailty Outcomes

Across the frailty outcome class, the corpus includes two direct clinical RCTs, several indirect observational or mechanistic cohorts, and multiple systematic reviews and meta-analyses. Amasene 2021 is a clinical RCT in post-hospitalized older adults evaluating resistance training plus leucine-enriched whey protein supplementation, with sarcopenia, frailty, body composition, and blood-based myokines as endpoints (Amasene 2021).

Quantitative findings in the frailty outcome class are heterogeneous and outcome-specific. Han 2024 frames sarcopenia risk as significantly higher in the <0.8 g/kg/day versus 0.8–1.x g/kg/day intake strata, and Li 2024 reports a random-effect meta-analysis with subgroup, meta-regression, and sensitivity analyses for gait speed (Han 2024; Li 2024). No numeric effect sizes, confidence intervals, or sample sizes are provided in the source fields beyond the p-values above, so per-study endpoint values are catalogued in the evidence synthesis rather than restated in prose.

Mechanistically, the frailty-sarcopenia axis is anchored by two human evidence streams in the corpus. Preclinical data are not represented in the frailty outcome class within the supplied sources; the mechanistic-to-clinical bridge here is therefore human-to-human, anchored in stable-isotope requirement studies (Wu 2025) and short-to-medium duration supplementation RCTs (Cereda 2022; Amasene 2021). The combined picture supports an anabolic-resistance rationale, with leucine-enriched whey as the most-studied delivery vehicle (Amasene 2021; Cereda 2022).

Within-corpus tensions in the frailty class fall into two channels. Wu 2025 reports a negative signal on the sarcopenia/frailty spectrum (P < 0.01, P = 0.0018) whereas Cereda 2022 is coded as null, again a partial conflict between an IAAO-anchored requirement study and a supplementation trial review (Wu 2025; Cereda 2022). Second, on directness, Amasene 2021 and Travers 2021 are the only direct clinical RCTs, while Li 2024, Kaminska 2023, Cheah 2023, and Han 2024 are review-level syntheses and Cereda 2022 and Wu 2025 are indirect; direct versus indirect evidence must be interpreted separately, since pooled review-level estimates (Li 2024 gait-speed meta-analysis; Kaminska 2023 whey protein meta-analysis) cannot be read as confirmatory of the direct RCT signals (Amasene 2021; Travers 2021; Li 2024; Kaminska 2023; Cheah 2023; Han 2024; Cereda 2022; Wu 2025).

### Immune and Inflammation Outcomes

A single quasi-experimental cohort (Merchant 2023) evaluated the impact of leucine-enriched protein supplementation with or without exercise in pre-frail older adults, yielding multiple inflammation-relevant contrasts across the study duration. The trial enrolled older adults and used a quasi-experimental design to assess physical function, body composition, and inflammation as co-primary endpoints, situating the inflammatory readout alongside functional outcomes rather than as an isolated biomarker. Directness is coded as indirect for this cohort because the intervention targets muscle anabolism with inflammation as a downstream secondary signal, and the effect direction on inflammatory endpoints is coded as unclear across the reported contrasts.

Because directness is indirect and effect direction is coded as unclear, these mixed significance values should be interpreted as hypothesis-generating rather than as confirmatory evidence of an anti-inflammatory effect of leucine-enriched supplementation in pre-frail older adults.

Mechanistically, the leucine-enriched protein substrate plausibly interfaces with inflammation through mTORC1-mediated anabolic signaling and through downstream modulation of cytokine expression in skeletal muscle, which is the human-study substrate invoked by Merchant 2023. The mechanistic substrate underlying this inflammatory finding rests on human biomarker data rather than on preclinical isolation, which is consistent with the indirect directness coding. The clinical RCT substrate for inflammation-specific endpoints in pre-frail older adults remains limited to this single cohort, so any translation from mechanistic plausibility to bedside anti-inflammatory effect remains untested by the present corpus.

Within-corpus tensions on the inflammation axis cannot be triangulated because Merchant 2023 is the only source assigned to the immune inflammation outcome class, so no within-class disagreement surfaces from the cross-study disagreement map. The absence of an orthogonal second source means that the inflammatory signal reported here cannot be corroborated or contradicted by a parallel directness-matched cohort, and the p-value spread (P = 0.005 through P > 0.05) is the only internal contrast available. By contrast with outcome classes that have multiple sources, the immune inflammation evidence base is structurally thin and can be interpreted as a single-cohort signal rather than as a converged field-level finding.

### Longevity Outcomes

A single observational cohort contributes evidence to the longevity outcome class within the Protein corpus. Sun 2021 is a prospective cohort study in adults that estimated hazard ratios (HRs) and 95% CIs for all-cause and cause-specific mortality associated with protein intake and major protein-source consumption, using Cox proportional hazards models as the primary analytic framework (Sun 2021). No specific endpoint p-values, sample size, or follow-up duration were extractable from the available source excerpts. The endpoint class is all-cause and cause-specific mortality, and the exposure dimension is the major dietary protein source rather than total protein quantity.

Quantitative findings within this outcome class are constrained by the depth of the available source excerpts. Sun 2021 reports HRs and 95% CIs for mortality associated with protein intake and major protein-source consumption, but the direction of association is coded as unclear in the curated evidence profile (Sun 2021). No p-values, exact hazard ratios, confidence interval bounds, sample sizes, or follow-up durations are present in the sources, so the prose cannot quote a specific numeric beyond the analytic-method descriptors above. The effect-direction coding of "unclear" therefore reflects absence of a directional signal in the extractable record rather than an explicit null finding.

Mechanistically, the longevity outcome class is the most distal endpoint captured in the Protein corpus and is rated as indirect in directness. A single observational cohort cannot, on its own, anchor mechanistic inference, and the corpus contains no clinical RCT or mechanistic human study that prospectively tests a protein-source manipulation against mortality endpoints with extractable effect sizes (Sun 2021). The mechanistic substrate that would link dietary protein source to all-cause mortality — including age-related changes in protein metabolism, anabolic resistance, and disease-specific pathways — is therefore not represented by source-traced quantitative data within this synthesis. The longevity claim therefore stands on epidemiologic association alone.

Within-corpus tensions specific to the longevity outcome class are not formally enumerated in the cross-study disagreement map, which contains no same-outcome non-orthogonal pairs. Because only one source (Sun 2021) populates this outcome class, no within-class disagreement can be surfaced; any apparent disagreement across the broader Protein corpus involves other outcome classes (muscle function, frailty, contextual other) and is therefore outside the scope of this subsection (Sun 2021). The evidence base for longevity as currently constituted is incomplete: a single indirect observational cohort with an unclear effect-direction coding cannot support broad clinical claims about protein intake and mortality.

### Muscle Function Outcomes

Five clinical RCTs evaluated direct endpoints for muscle function in adult and older-adult populations, with follow-up windows ranging from 12 weeks to 12 months. Huschtscha 2021 randomized healthy active older adults to a high-protein dairy milk beverage with or without progressive resistance training over 12 weeks, measuring fat-free mass, skeletal muscle strength, power, and functional performance (Huschtscha 2021). Bulow 2023 investigated 1-year daily protein supplementation with or without physical exercise on muscle protein synthesis rate and the muscle metabolome in healthy older Danes (Bulow 2023). Peng 2024 reported a dose of 1.0 g/kg/day. Salas-Groves 2024 tested web-based culinary medicine in older adults (Salas-Groves 2024). Outcome classes were uniformly muscle function, with directness ratings of direct and effect directions ranging from negative through null to unclear across these RCTs.

Direct RCT evidence for muscle-related endpoints is mixed. Bulow 2023 noted within-group effects at P < 0.0001 but limited between-arm separation, while Justesen 2022 reported essentially identical outcomes between distribution patterns (P = 0.647 and P = 0.306). Peng 2024 reported six p-values in the range P = 0.006 to P = 0.04 across the trial's functional endpoints. Jackson 2022 reported protein intake increases from 0.8 ± 0.2 to 1.2 ± 0.3 g/kg in the not-coached group (n = 28, P < 0.001). Reference the evidence synthesis (Per-Study Endpoint Evidence) carries the exhaustive per-study × per-endpoint p-value and effect-size mapping, so only representative values are repeated here.

In a clinical RCT of sarcopenia-relevant populations, Justesen 2022 found that skewed versus even distribution did not modify the MPS readout at the population level (P = 0.647), while Bulow 2023 captured longitudinal metabolomic signatures that may explain why between-arm comparisons appear muted despite robust within-group changes (P < 0.0001). Preclinical data informing this bridge are not themselves sources in the corpus, but the trials above operationalize the relevant comparator arms.

### Deficiency Prevalence Outcomes

The source states that dileucine-supplemented essential amino acids support whole-body anabolism after resistance exercise and serum-stimulated cell-based anabolism, but the quantitative read-out is mixed. Strongly positive contrasts include P < 0.0001 (appears twice), P < 0.001, P = 0.002, and P = 0.003 for the anabolic endpoints, whereas plausibly null contrasts include P = 0.68, P = 0.31, P = 0.59, P = 0.39, P = 0.50, P = 0.55, P = 0.678, and P = 0.583 for secondary or comparator outcomes. Per the evidence synthesis (Per-Study Endpoint Evidence), the per-study × p-value tuple for Aguilera 2025 is reproduced verbatim, and the prose above references rather than restates each individual entry.

Deficiency Prevalence remains a separate Results slice for Protein supplementation (n=1; claims=74; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

## Cross-Domain Synthesis

The signature tension in the Protein corpus is between mechanistic/biomarker plausibility (the leucine trigger, mTORC1-driven muscle protein synthesis, mitochondrial anabolism) and a body of human functional-endpoint RCTs that is, at best, mixed and, at worst, negative or null on the very outcomes the mechanism would predict. Peng 2024 reported a dose of 1.0 g/kg/day. This pattern is exactly the surrogate-versus-hard-outcome problem Ioannidis 2005 warns about: an intervention can move a proximal biomarker (muscle protein synthesis, plasma leucine) without translating into measurable strength, mass, or functional gain, and the corpus gives us no trial that simultaneously confirms a mechanistic biomarker response and a clinically meaningful functional response in the same cohort. The boundary condition appears to be baseline intake: when habitual protein intake is already adequate, additional supplementation may produce null or negative results, whereas undernourished or sarcopenic populations retain room for detectable benefit. Resolving this would require trials that pre-stratify or enroll on baseline intake and report both biomarker and functional endpoints side by side, which the current corpus does not provide.

A second load-bearing tension is the direct-versus-indirect evidence gap on the frailty outcome class. By contrast, the indirect and review evidence on frailty is mixed: Wu 2025 (indirect) reports a negative finding on protein requirements in sarcopenic older adults, while Cereda 2022 (indirect) and the review by Kaminska 2023 describe a null picture, and Han 2024 (review) and Cheah 2023 (review) summarize observational and trial data with unclear direction. The mechanism-vs-clinical boundary here is sharper than for muscle function because no single direct trial unambiguously reverses frailty with protein supplementation alone, and the surrogate endpoint caution (Ioannidis 2005) applies in full force when a mechanistic claim about leucine or HMB is invoked to justify frailty reversal. The boundary condition seems is that frailty a syndromic endpoint requiring multicomponent intervention; protein alone may be necessary but insufficient, so its effect is confounded by the co-administered resistance training and coaching present in nearly every positive signal. Resolving the tension would require factorial trials that isolate the protein arm from the exercise arm and report frailty scores, not just sarcopenia prevalence, as a primary endpoint.

Another tension concerns the transferability of model-system and surrogate signals into the cardiometabolic and longevity outcome classes that some readers would want to claim. The boundary condition is that lifespan and hard cardiometabolic events are downstream of muscle and metabolic changes by years or decades, so short-term surrogate movement cannot be read across the inferential bridge as longevity evidence; the Ioannidis 2005 caution applies here at its strongest. Resolving this would require either very long-duration RCTs with hard endpoints (currently absent from the corpus) or explicit acknowledgment that any longevity or cardiometabolic inference is hypothesis-generating rather than confirmatory, which the present synthesis adopts as its working posture.

A sixth and final tension is the population-to-population transfer gap, which is itself a load-bearing boundary condition. Pooling these populations under a single protein-nutrition claim would violate the indirectness principle and the surrogate-endpoint caution (Ioannidis 2005) simultaneously. The boundary condition is that the corpus's apparent contradictions largely resolve once population is held fixed: undernourished or catabolic populations (hemodialysis, post-hospitalization, low baseline intake) cluster around positive mechanistic or feasibility signals, whereas healthy active or well-nourished older adults cluster around null or negative clinical-endpoint results. The inferential bridge from biomarker to bedside is therefore not merely untested by the corpus but actively stratified by baseline intake and clinical state; any cross-population claim should be hedged accordingly. Resolution would require harmonized intake-baseline reporting and population-stratified meta-analyses, which the available reviews (Nunes 2022, Cuyul-Vasquez 2023, Chang 2023, Nasimi 2023, Khalafi 2025, Pearson 2022) only partially achieve because their primary strata are age and resistance-exercise co-intervention rather than baseline intake.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.
## Discussion

**Thesis:** Across 41 curated reference papers, the evidence base for Protein shows a context-dependent profile. Positive signals appear in: muscle function, contextual other. Negative signals appear in: muscle function, frailty. Null findings dominate: muscle function, frailty. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Protein broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 41 included sources. The evidence-tier distribution is: B2 (n=24), A1 (n=11), B1 (n=6). By directness, the breakdown is: indirect (n=17), review (n=13), direct (n=11). 30 of 41 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: older adults; frail / sarcopenic adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus of 41 sources over-represents short-term, mechanism-anchored, indirect evidence and under-represents the large, long-duration randomized trials that would be needed to anchor hard clinical claims. Direct randomized functional-endpoint trials in community-dwelling older adults are concentrated in 12-16 week interventions such as Huschtscha 2021 (P < 0.05 to P = 0.001 across endpoints), Bulow 2023 (P < 0.0001 for one biomarker, mostly null otherwise), and Kirk 2021 (P < 0.001 to P = 0.048), and there is no long-term mortality or hard-outcome randomized trial for protein supplementation in non-diabetic older adults within the corpus. Mortality-relevant evidence in this set is restricted to a single observational cohort, Sun 2021, which provides hazard-ratio estimates rather than randomized inference; combined with Travers 2021's primary-care frailty trial protocol (no long-term mortality trial in this corpus) and the absence of any trial with follow-up beyond roughly 12 months among the directly functional RCTs (except Bulow 2023 at 12 months, which was mechanistic), the headline conclusion that higher protein intake improves muscle or frailty outcomes cannot be transitively extended to disability, hospitalization, or mortality endpoints.

Several clinically important outcomes are touched by only one source in the corpus, which means within-corpus replication of those findings is not possible and any single-trial result must be treated as preliminary. Intradialytic parenteral nutrition in maintenance hemodialysis patients with protein-energy wasting is supported by exactly one direct RCT, Kittiskulnam 2022 (P < 0.01 to P < 0.05 across biomarkers, P = 0.001 to P = 0.005 for selected endpoints), which is therefore the sole within-corpus anchor for ESRD-specific clinical recommendations. Because each of these populations and delivery modes rests on a single source, external validity cannot be assessed from the corpus itself, and any inference beyond that single trial is outside the evidence base.

Population specificity is a binding constraint: most direct RCTs enrolled healthy, community-dwelling, active older adults rather than the frail, sarcopenic, multimorbid, or hospitalized groups in whom protein supplementation is most often clinically recommended. The evidence tiers are B2 (n=24), A1 (n=11), B1 (n=6), and directness is indirect (n=17), review (n=13), direct (n=11). Effect directions are unclear (n=20), positive (n=7), null (n=6), negative (n=4), mixed (n=4), with 30 sources carrying source-traced p-values and 350 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 41 included sources on Protein Nutrition across 7 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the disagreement between Kwon 2023 and Jackson 2022 on muscle function (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Nunes 2022, Pearson 2022, Nasimi 2023, Chang 2023, Cheah 2023) emphasize convergent signals on Protein Nutrition. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| frailty | 2 | 6 | negative, null, unclear | conflict-resolution gap |
| muscle function | 6 | 14 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| deficiency prevalence | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 3 | 4 | mixed, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P3 | frailty: conflict-resolution gap | 2 direct and 6 indirect sources; direction profile: negative, null, unclear |
| P4 | muscle function: conflict-resolution gap | 6 direct and 14 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P5 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |

### Next-Study Design Recommendation

The next high-yield study for Protein Nutrition should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Huschtscha 2021; tier=A1; directness=direct; endpoint=muscle function; direction=negative; representative statistic=P < 0.001.
- Kittiskulnam 2022; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P = 0.001.
- Kirk 2021; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Bulow 2023; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=P < 0.0001.
- Salas-Groves 2024; tier=A1; directness=direct; endpoint=muscle function; direction=null; representative statistic=P = 0.08.
- Peng 2024; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=P = 0.006.
- Helder 2020; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P = 0.001.
- Justesen 2022; tier=A1; directness=direct; endpoint=muscle function; direction=null; representative statistic=P = 0.306.
- Santos 2023; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=P = 0.007.
- Amasene 2021; tier=A1; directness=direct; endpoint=frailty; direction=negative; representative statistic=P < 0.005.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Huschtscha 2021: outcome=muscle function; directness=direct; tier=A1; direction=negative; claims=193.
- Kittiskulnam 2022: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=151.
- Kirk 2021: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=117.
- Bulow 2023: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=90.
- Salas-Groves 2024: outcome=muscle function; directness=direct; tier=A1; direction=null; claims=75.
- Peng 2024: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=62.
- Helder 2020: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=53.
- Justesen 2022: outcome=muscle function; directness=direct; tier=A1; direction=null; claims=42.
- Santos 2023: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=26.
- Amasene 2021: outcome=frailty; directness=direct; tier=A1; direction=negative; claims=21.
- Travers 2021: outcome=frailty; directness=direct; tier=A1; direction=null; claims=11.
- Nunes 2022: outcome=muscle function; directness=review; tier=B1; direction=mixed; claims=99.
- Pearson 2022: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=75.
- Chang 2023: outcome=muscle function; directness=review; tier=B1; direction=mixed; claims=38.
- Nasimi 2023: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=38.
- Cheah 2023: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=11.
- Li 2024: outcome=frailty; directness=review; tier=B1; direction=unclear; claims=3.
- Griffen 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=191.
- Jackson 2022: outcome=muscle function; directness=indirect; tier=B2; direction=negative; claims=154.
- Khalafi 2025: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=112.
- Han 2024: outcome=frailty; directness=review; tier=B2; direction=unclear; claims=96.
- Merchant 2023: outcome=immune inflammation; directness=indirect; tier=B2; direction=unclear; claims=84.
- Stahn 2020: outcome=muscle function; directness=indirect; tier=B2; direction=positive; claims=75.
- Aguilera 2025: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=unclear; claims=74.
- Jacob 2021: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=73.
- So 2020: outcome=muscle function; directness=indirect; tier=B2; direction=positive; claims=52.
- Kalyva 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=49.
- Wu 2025: outcome=frailty; directness=indirect; tier=B2; direction=negative; claims=46.
- Cuyul-Vasquez 2023: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=45.
- Hashimoto 2020: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=44.
- Sun 2021: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=41.
- Hoekstra 2024: outcome=muscle function; directness=indirect; tier=B2; direction=mixed; claims=40.
- Kaminska 2023: outcome=frailty; directness=review; tier=B2; direction=unclear; claims=36.
- Kwon 2023: outcome=muscle function; directness=review; tier=B2; direction=positive; claims=33.
- Noh 2023: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=32.
- Ijaz 2025: outcome=muscle function; directness=indirect; tier=B2; direction=positive; claims=20.
- Kwok 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=20.
- Cereda 2022: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=8.
- Honaga 2022: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=7.
- Yang 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=3.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 5 disagreement: Kwon 2023 vs Jackson 2022; Kwon 2023 reports positive effect on muscle function; Jackson 2022 reports negative on the same outcome — direct conflict
- Severity 5 disagreement: Ijaz 2025 vs Jackson 2022; Ijaz 2025 reports positive effect on muscle function; Jackson 2022 reports negative on the same outcome — direct conflict
- Severity 5 disagreement: Stahn 2020 vs Jackson 2022; Stahn 2020 reports positive effect on muscle function; Jackson 2022 reports negative on the same outcome — direct conflict
- Severity 5 disagreement: So 2020 vs Jackson 2022; So 2020 reports positive effect on muscle function; Jackson 2022 reports negative on the same outcome — direct conflict
- Severity 4 null vs negative: Salas-Groves 2024 vs Huschtscha 2021; Huschtscha 2021 (negative on muscle function) vs Salas-Groves 2024 (null on muscle function) — partial conflict
- Severity 4 null vs negative: Wu 2025 vs Cereda 2022; Wu 2025 (negative on frailty) vs Cereda 2022 (null on frailty) — partial conflict
- Severity 4 null vs negative: Huschtscha 2021 vs Justesen 2022; Huschtscha 2021 (negative on muscle function) vs Justesen 2022 (null on muscle function) — partial conflict
- Severity 4 null vs negative: Travers 2021 vs Amasene 2021; Amasene 2021 (negative on frailty) vs Travers 2021 (null on frailty) — partial conflict

## Conclusion

For Protein supplementation, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support Protein supplementation as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone longevity intervention with proven hard clinical-outcome effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

## References

- **Huschtscha 2021.** _The Effects of a High-Protein Dairy Milk Beverage With or Without Progressive Resistance Training on Fat-Free Mass, Skeletal Muscle Strength and Power, and Functional Performance in Healthy Active Older Adults: A 12-Week Randomized Controlled Trial._ Frontiers in Nutrition, 2021. DOI: 10.3389/fnut.2021.644865 PMID: 33816540.
- **Griffen 2022.** _Changes in 24‐h energy expenditure, substrate oxidation, and body composition following resistance exercise and a high protein diet via whey protein supplementation in healthy older men._ Physiological Reports, 2022. DOI: 10.14814/phy2.15268 PMID: 37815091.
- **Jackson 2022.** _Effectiveness of a Per-Meal Protein Prescription and Nutrition Education with versus without Diet Coaching on Dietary Protein Intake and Muscle Health in Middle-Aged Women._ Nutrients, 2022. DOI: 10.3390/nu14020375 PMID: 35057556.
- **Kittiskulnam 2022.** _The beneficial effects of intradialytic parenteral nutrition in hemodialysis patients with protein energy wasting: a prospective randomized controlled trial._ Scientific Reports, 2022. DOI: 10.1038/s41598-022-08726-8 PMID: 35296793.
- **Kirk 2021.** _Leucine‐enriched whey protein supplementation, resistance‐based exercise, and cardiometabolic health in older adults: a randomized controlled trial._ Journal of Cachexia, Sarcopenia and Muscle, 2021. DOI: 10.1002/jcsm.12805 PMID: 34520104.
- **Khalafi 2025.** _Effects of Whey Protein Supplementation on Body Composition, Muscular Strength, and Cardiometabolic Health in Older Adults: A Systematic Review with Pairwise Meta-Analysis._ Healthcare, 2025. DOI: 10.3390/healthcare13212814 PMID: 41228181.
- **Nunes 2022.** _Systematic review and meta‐analysis of protein intake to support muscle mass and function in healthy adults._ Journal of Cachexia, Sarcopenia and Muscle, 2022. DOI: 10.1002/jcsm.12922 PMID: 35187864.
- **Han 2024.** _Association of Protein Intake with Sarcopenia and Related Indicators Among Korean Older Adults: A Systematic Review and Meta-Analysis._ Nutrients, 2024. DOI: 10.3390/nu16244350 PMID: 39770971.
- **Bulow 2023.** _Effect of 1-year daily protein supplementation and physical exercise on muscle protein synthesis rate and muscle metabolome in healthy older Danes: a randomized controlled trial._ European Journal of Nutrition, 2023. DOI: 10.1007/s00394-023-03182-0 PMID: 37266586.
- **Merchant 2023.** _Impact of exercise and leucine-enriched protein supplementation on physical function, body composition, and inflammation in pre-frail older adults: a quasi-experimental study._ Frontiers in Medicine, 2023. DOI: 10.3389/fmed.2023.1204198 PMID: 37644985.
- **Pearson 2022.** _The impact of dietary protein supplementation on recovery from resistance exercise-induced muscle damage: A systematic review with meta-analysis._ European Journal of Clinical Nutrition, 2022. DOI: 10.1038/s41430-022-01250-y PMID: 36513777.
- **Salas-Groves 2024.** _The Effect of Web-Based Culinary Medicine to Enhance Protein Intake on Muscle Quality in Older Adults: Randomized Controlled Trial._ JMIR Formative Research, 2024. DOI: 10.2196/49322 PMID: 38349721.
- **Stahn 2020.** _Combined protein and calcium β-hydroxy-β-methylbutyrate induced gains in leg fat free mass: a double-blinded, placebo-controlled study._ Journal of the International Society of Sports Nutrition, 2020. DOI: 10.1186/s12970-020-0336-1 PMID: 32164702.
- **Aguilera 2025.** _Dileucine-supplemented essential amino acids support whole-body anabolism after resistance exercise and serum-stimulated cell-based anabolism._ Journal of the International Society of Sports Nutrition, 2025. DOI: 10.1080/15502783.2025.2590090 PMID: 41321015.
- **Jacob 2021.** _Mitochondrial Content, but Not Function, Is Altered With a Multimodal Resistance Training Protocol and Adequate Protein Intake in Leucine-Supplemented Pre/Frail Women._ Frontiers in Nutrition, 2021. DOI: 10.3389/fnut.2020.619216 PMID: 33553232.
- **Peng 2024.** _Protein‐enriched soup and weekly exercise improve muscle health: A randomized trial in mid‐to‐old age with inadequate protein intake._ Journal of Cachexia, Sarcopenia and Muscle, 2024. DOI: 10.1002/jcsm.13481 PMID: 38641937.
- **Helder 2020.** _Blended home‐based exercise and dietary protein in community‐dwelling older adults: a cluster randomized controlled trial._ Journal of Cachexia, Sarcopenia and Muscle, 2020. DOI: 10.1002/jcsm.12634 PMID: 33103379.
- **So 2020.** _Effect of Dairy Protein Intake on Muscle Mass among Korean Adults: A Prospective Cohort Study._ Nutrients, 2020. DOI: 10.3390/nu12092537 PMID: 32825743.
- **Kalyva 2026.** _Effects of Higher Dietary Protein Intake on Isokinetic Muscle Performance in Older Adults with Type 2 Diabetes Mellitus._ Journal of Functional Morphology and Kinesiology, 2026. DOI: 10.3390/jfmk11010125 PMID: 41900532.
- **Wu 2025.** _Dietary protein requirements of older adults with sarcopenia determined by the indicator amino acid oxidation technology._ Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1486482 PMID: 40093878.
- **Cuyul-Vasquez 2023.** _Effectiveness of Whey Protein Supplementation during Resistance Exercise Training on Skeletal Muscle Mass and Strength in Older People with Sarcopenia: A Systematic Review and Meta-Analysis._ Nutrients, 2023. DOI: 10.3390/nu15153424 PMID: 37571361.
- **Hashimoto 2020.** _Effect of Exercise Habit on Skeletal Muscle Mass Varies with Protein Intake in Elderly Patients with Type 2 Diabetes: A Retrospective Cohort Study._ Nutrients, 2020. DOI: 10.3390/nu12103220 PMID: 33096793.
- **Justesen 2022.** _Comparing Even with Skewed Dietary Protein Distribution Shows No Difference in Muscle Protein Synthesis or Amino Acid Utilization in Healthy Older Individuals: A Randomized Controlled Trial._ Nutrients, 2022. DOI: 10.3390/nu14214442 PMID: 36364705.
- **Sun 2021.** _Association of Major Dietary Protein Sources With All‐Cause and Cause‐Specific Mortality: Prospective Cohort Study._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021. DOI: 10.1161/JAHA.119.015553 PMID: 33624505.
- **Hoekstra 2024.** _The effect of home‐based neuromuscular electrical stimulation‐resistance training and protein supplementation on lean mass in persons with spinal cord injury: A pilot study._ Physiological Reports, 2024. DOI: 10.14814/phy2.70073 PMID: 39358836.
- **Nasimi 2023.** _Whey Protein Supplementation with or without Vitamin D on Sarcopenia-Related Measures: A Systematic Review and Meta-Analysis._ Advances in Nutrition, 2023. DOI: 10.1016/j.advnut.2023.05.011 PMID: 37196876.
- **Chang 2023.** _Effects of Whey Protein, Leucine, and Vitamin D Supplementation in Patients with Sarcopenia: A Systematic Review and Meta-Analysis._ Nutrients, 2023. DOI: 10.3390/nu15030521 PMID: 36771225.
- **Kaminska 2023.** _The Impact of Whey Protein Supplementation on Sarcopenia Progression among the Elderly: A Systematic Review and Meta-Analysis._ Nutrients, 2023. DOI: 10.3390/nu15092039 PMID: 37432157.
- **Kwon 2023.** _Improved Muscle Mass and Function With Protein Supplementation in Older Adults With Sarcopenia: A Meta-Analysis._ Annals of Rehabilitation Medicine, 2023. DOI: 10.5535/arm.23076 PMID: 37907227.
- **Noh 2023.** _Effects of resistance training and protein supplementation interventions on muscle volume and muscle function: sex differences in humans._ Physical Activity and Nutrition, 2023. DOI: 10.20463/pan.2023.0033 PMID: 38297472.
- **Santos 2023.** _Effects of Whey Protein Isolate on Body Composition, Muscle Mass, and Strength of Chronic Heart Failure Patients: A Randomized Clinical Trial._ Nutrients, 2023. DOI: 10.3390/nu15102320 PMID: 37242203.
- **Amasene 2021.** _Effects of Resistance Training Intervention along with Leucine-Enriched Whey Protein Supplementation on Sarcopenia and Frailty in Post-Hospitalized Older Adults: Preliminary Findings of a Randomized Controlled Trial._ Journal of Clinical Medicine, 2021. DOI: 10.3390/jcm11010097 PMID: 35011838.
- **Kwok 2023.** _Exploring the short‐term impact of swapping consumption from standard protein snacks to higher protein snacks on energy intake in social drinkers: Is protein worth a nudge?._ Food Science & Nutrition, 2023. DOI: 10.1002/fsn3.3902 PMID: 38455182.
- **Ijaz 2025.** _Enhancing Muscle Quality: Exploring Leucine and Whey Protein in Sarcopenic Individuals._ Journal of Cachexia, Sarcopenia and Muscle, 2025. DOI: 10.1002/jcsm.70060 PMID: 40937507.
- **Cheah 2023.** _Benefits and side effects of protein supplementation and exercise in sarcopenic obesity: A scoping review._ Nutrition Journal, 2023. DOI: 10.1186/s12937-023-00880-7 PMID: 37872544.
- **Travers 2021.** _Protocol for a randomised controlled trial of a primary care intervention to Reverse Frailty and Enhance Resilience through Exercise and dietary protein Education (REFEREE) in community-dwelling adults aged 65 and over._ HRB Open Research, 2021. DOI: 10.12688/hrbopenres.13188.2 PMID: 33977224.
- **Cereda 2022.** _Whey Protein, Leucine-and Vitamin-D-Enriched Oral Nutritional Supplementation for the Treatment of Sarcopenia._ Nutrients, 2022. DOI: 10.3390/nu14071524 PMID: 35406137.
- **Honaga 2022.** _Investigation of the Effect of Nutritional Supplementation with Whey Protein and Vitamin D on Muscle Mass and Muscle Quality in Subacute Post-Stroke Rehabilitation Patients: A Randomized, Single-Blinded, Placebo-Controlled Trial._ Nutrients, 2022. DOI: 10.3390/nu14030685 PMID: 35277045.
- **Li 2024.** _Effect of Protein Supplementation Combined With Resistance Training in Gait Speed in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ J Aging Phys Act, 2024. DOI: 10.1123/japa.2023-0285 PMID: 38753309.
- **Yang 2024.** _FEASIBILITY OF WHEY PROTEIN SUPPLEMENTATION TO IMPROVE OLDER ADULT FUNCTION POST-HOSPITALIZATION._ Innovation in Aging, 2024. DOI: 10.1093/geroni/igae098.3982
- **Zaromskyte 2021.** _Evaluating the Leucine Trigger Hypothesis to Explain the Post-prandial Regulation of Muscle Protein Synthesis in Young and Older Adults: A Systematic Review._ Frontiers in Nutrition, 2021. DOI: 10.3389/fnut.2021.685165 PMID: 34307436.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "99726ddc-88c3-4af4-bfb3-45db23fb7732",
  "title": "Research Synthesis: Protein supplementation \u2014 full paper"
}